Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders
May 23 2024 - 12:00PM
Sequana Medical announces results of Annual and Extraordinary
General Meetings of Shareholders
PRESS RELEASEREGULATED
INFORMATION23 May 2024, 06:00 pm CEST
Ghent, Belgium – 23 May 2024
– Sequana Medical NV (Euronext Brussels: SEQUA)
(the "Company" or "Sequana
Medical"), a pioneer in the treatment of fluid
overload in liver disease, heart failure and cancer, today
announces that all proposed resolutions submitted to the Annual and
Extraordinary General Meetings of Shareholders were approved at the
meetings held today at 09:00 am CEST.
The items on the agendas of the meetings
included (among other) the approval of a number of resolutions
relating to the financial year ended 31 December 2023, the approval
of the revised remuneration policy, the reappointment of the
statutory auditor, certain approvals in accordance with Article
7:151 of the Belgian Companies and Associations Code, the approval
of the contribution in kind of certain receivables pursuant to the
unsecured and subordinated convertible loan agreement entered into
on 7 February 2024 between the Company and Partners in Equity and
Rosetta Capital in the principal amount of EUR 3,041,507.59, as
well as the renewal of the authorization to the Board of Directors
to increase the share capital within the framework of the
authorised capital.
The minutes of the shareholders' meetings, as
well as the revised versions of the Company's articles
ofassociation, can be accessed on the Company’s website.
For more information, please
contact:
Sequana Medical
Ian CrosbieChief Executive OfficerE:
IR@sequanamedical.com T: +44 7973 42 99 17
About Sequana Medical
Sequana Medical NV is a pioneer in treating
fluid overload, a serious and frequent clinical complication in
patients with liver disease, heart failure and cancer. This causes
major medical issues including increased mortality, repeated
hospitalizations, severe pain, difficulty breathing and restricted
mobility. Although diuretics are standard of care, they become
ineffective, intolerable or exacerbate the problem in many
patients. There are limited effective treatment options, resulting
in poor clinical outcomes, high costs and a major impact on their
quality of life. Sequana Medical is seeking to provide innovative
treatment options for this large and growing "diuretic-resistant"
patient population.
alfapump® and DSR® are Sequana
Medical's proprietary platforms that work with the body to treat
diuretic-resistant fluid overload, delivering major clinical and
quality of life benefits for patients and reducing costs for
healthcare systems.
The Company’s Premarket Approval (PMA)
application for the alfapump was submitted to
the US FDA in December 2023 and accepted for substantive review in
January 2024, having reported positive primary and secondary
endpoint data from the North American pivotal POSEIDON study in
recurrent or refractory ascites due to liver cirrhosis. US
market approval of the alfapump is
anticipated before the end of Q1 2025 with US commercial launch
planned for H2 2025.
Results of the Company's RED DESERT and SAHARA
proof-of-concept studies in heart failure support DSR's mechanism
of action as breaking the vicious cycle of cardiorenal syndrome.
All three patients from the non-randomized cohort of MOJAVE, a US
randomized controlled multi-center Phase 1/2a clinical study, have
been successfully treated with DSR, resulting in a dramatic
improvement in diuretic response and virtual elimination of loop
diuretic requirements. The independent Data Safety Monitoring Board
approved the start of the randomized MOJAVE cohort of up to a
further 30 patients, which is planned after
alfapump US PMA approval.
Sequana Medical is listed on the regulated
market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in
Ghent, Belgium. For further information, please visit
www.sequanamedical.com.
Important Regulatory
Disclaimers
The alfapump® system is
currently not approved in the United States or Canada. In the
United States and Canada, the alfapump system is
currently under clinical investigation (POSEIDON Trial) and is
being studied in adult patients with refractory or recurrent
ascites due to liver cirrhosis. DSR® therapy is still in
development and it should be noted that any statements regarding
safety and efficacy arise from ongoing pre-clinical and clinical
investigations which have yet to be completed. There is no link
between DSR therapy and ongoing investigations with the
alfapump system in Europe, the United States or
Canada.
Note: alfapump® and DSR® are
registered trademarks.
Forward-looking statements
This press release may contain predictions,
estimates or other information that might be considered
forward-looking statements. Such forward-looking statements are not
guarantees of future performance. These forward-looking statements
represent the current judgment of Sequana Medical on what the
future holds, and are subject to risks and uncertainties that could
cause actual results to differ materially. Sequana Medical
expressly disclaims any obligation or undertaking to release any
updates or revisions to any forward-looking statements in this
press release, except if specifically required to do so by law or
regulation. You should not place undue reliance on forward-looking
statements, which reflect the opinions of Sequana Medical only as
of the date of this press release.
- Sequana Medical NV - AGM EGM 2024 - Results PR (DUT)
- Sequana Medical NV - AGM EGM 2024 - Results PR (ENG)